A federal judge in West Virginia denied Regeneron's request for an injunction against Amgen's Pavblu, creating uncertainty around Eylea's U.S. market exclusivity. At the time, Leerink's Risinger ...

Equities research analysts at Leerink Partnrs reduced their Q1 2025 EPS estimates for shares of Regeneron Pharmaceuticals in a research report issued on Tuesday, April 1st. Leerink Partnrs analyst D.

Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN – Get Free Report) shares reached a new 52-week low on Monday after JPMorgan Chase & Co. lowered their price target on the stock from $1,100.00 to ...

The Cambridge, Massachusetts-based biotech had divested its cell therapy R&D programs to Regeneron for $5 million upfront in early 2024. As the Leerink team noted, the company’s remaining ...

Should Regeneron wish to compete, they will have to lower their prices, thereby eating into their profit margins. Interestingly, at the recent Leerink Global Healthcare Conference, the CFO Chris ...

In a report released on March 2, David Risinger from Leerink Partners maintained a ... AnaptysBio, and Regeneron. According to TipRanks, Risinger has an average return of 10.3% and a 56.15% ...

Leerink analyst Andrew Berens notes that Outperform-rated Incyte (INCY) has reported the results of the two parallel Phase 3 trials evaluating povorcitinib in hidradenitis suppurativa, STOP-HS1 ...

Leerink lowered the firm’s price target on AirSculpt Technologies (AIRS) to $2.50 from $6.50 and keeps a Market Perform rating on the shares. Q4 results featured a continuation of challenges ...

In addition to the presentation, company management will be available to participate in one-on-one meetings with investors who are registered attendees of the conference. A webcast of the ...

Jonathon Whitton, AuD, PhD, VP, auditory global program head, Regeneron, discusses regulatory challenges for DB-OTO, Regeneron’s AAV-based gene therapy for hearing loss. Last month, Regeneron ...